These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 27225724

  • 1. Effects of Genetic Polymorphism in CYP3A4 and CYP3A5 Genes on Tacrolimus Dose Among Kidney Transplant Recipients.
    Yousef AM, Qosa H, Bulatova N, Abuhaliema A, Almadhoun H, Khayyat G, Olemat M.
    Iran J Kidney Dis; 2016 May; 10(3):156-63. PubMed ID: 27225724
    [Abstract] [Full Text] [Related]

  • 2. Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients.
    Kagaya H, Niioka T, Saito M, Inoue T, Numakura K, Yamamoto R, Akamine Y, Habuchi T, Satoh S, Miura M.
    Int J Mol Sci; 2018 Mar 16; 19(3):. PubMed ID: 29547545
    [Abstract] [Full Text] [Related]

  • 3. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
    Nair SS, Sarasamma S, Gracious N, George J, Anish TS, Radhakrishnan R.
    Exp Clin Transplant; 2015 Apr 16; 13 Suppl 1():197-200. PubMed ID: 25894154
    [Abstract] [Full Text] [Related]

  • 4. CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients.
    Li DY, Teng RC, Zhu HJ, Fang Y.
    Int J Clin Pharmacol Ther; 2013 Jun 16; 51(6):466-74. PubMed ID: 23557867
    [Abstract] [Full Text] [Related]

  • 5. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
    Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, van Gelder T.
    Clin Pharmacol Ther; 2003 Sep 16; 74(3):245-54. PubMed ID: 12966368
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.
    Lloberas N, Elens L, Llaudó I, Padullés A, van Gelder T, Hesselink DA, Colom H, Andreu F, Torras J, Bestard O, Cruzado JM, Gil-Vernet S, van Schaik R, Grinyó JM.
    Pharmacogenet Genomics; 2017 Sep 16; 27(9):313-322. PubMed ID: 28704257
    [Abstract] [Full Text] [Related]

  • 8. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
    Muller WK, Dandara C, Manning K, Mhandire D, Ensor J, Barday Z, Freercks R.
    S Afr Med J; 2020 Jan 29; 110(2):159-166. PubMed ID: 32657689
    [Abstract] [Full Text] [Related]

  • 9. Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients.
    Yildirim E, Şahin G, Kaltuş Z, Çolak E.
    Clin Lab; 2019 Nov 01; 65(11):. PubMed ID: 31710427
    [Abstract] [Full Text] [Related]

  • 10. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
    Jun KR, Lee W, Jang MS, Chun S, Song GW, Park KT, Lee SG, Han DJ, Kang C, Cho DY, Kim JQ, Min WK.
    Transplantation; 2009 Apr 27; 87(8):1225-31. PubMed ID: 19384171
    [Abstract] [Full Text] [Related]

  • 11. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
    Zuo XC, Ng CM, Barrett JS, Luo AJ, Zhang BK, Deng CH, Xi LY, Cheng K, Ming YZ, Yang GP, Pei Q, Zhu LJ, Yuan H, Liao HQ, Ding JJ, Wu D, Zhou YN, Jing NN, Huang ZJ.
    Pharmacogenet Genomics; 2013 May 27; 23(5):251-61. PubMed ID: 23459029
    [Abstract] [Full Text] [Related]

  • 12. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients.
    Lunde I, Bremer S, Midtvedt K, Mohebi B, Dahl M, Bergan S, Åsberg A, Christensen H.
    Eur J Clin Pharmacol; 2014 Jun 27; 70(6):685-93. PubMed ID: 24658827
    [Abstract] [Full Text] [Related]

  • 13. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
    Deininger KM, Vu A, Page RL, Ambardekar AV, Lindenfeld J, Aquilante CL.
    Clin Transplant; 2016 Sep 27; 30(9):1074-81. PubMed ID: 27314545
    [Abstract] [Full Text] [Related]

  • 14. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
    Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van Gelder T, van Schaik RH.
    Clin Chem; 2011 Nov 27; 57(11):1574-83. PubMed ID: 21903774
    [Abstract] [Full Text] [Related]

  • 15. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
    Shi Y, Li Y, Tang J, Zhang J, Zou Y, Cai B, Wang L.
    Gene; 2013 Jan 10; 512(2):226-31. PubMed ID: 23107770
    [Abstract] [Full Text] [Related]

  • 16. Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations.
    Niioka T, Kagaya H, Saito M, Inoue T, Numakura K, Yamamoto R, Habuchi T, Satoh S, Miura M.
    Clin Exp Nephrol; 2017 Oct 10; 21(5):787-796. PubMed ID: 28271256
    [Abstract] [Full Text] [Related]

  • 17. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.
    Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y.
    Clin Pharmacol Ther; 2007 Dec 10; 82(6):711-25. PubMed ID: 17495880
    [Abstract] [Full Text] [Related]

  • 18. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
    Zhang JJ, Liu SB, Xue L, Ding XL, Zhang H, Miao LY.
    Int J Clin Pharmacol Ther; 2015 Sep 10; 53(9):728-36. PubMed ID: 26227094
    [Abstract] [Full Text] [Related]

  • 19. Long-Term Influence of CYP3A5, CYP3A4, ABCB1, and NR1I2 Polymorphisms on Tacrolimus Concentration in Chinese Renal Transplant Recipients.
    Liu F, Ou YM, Yu AR, Xiong L, Xin HW.
    Genet Test Mol Biomarkers; 2017 Nov 10; 21(11):663-673. PubMed ID: 28945481
    [Abstract] [Full Text] [Related]

  • 20. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients.
    Roy JN, Barama A, Poirier C, Vinet B, Roger M.
    Pharmacogenet Genomics; 2006 Sep 10; 16(9):659-65. PubMed ID: 16906020
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.